Alzheimer Patient Articles & Analysis
19 news found
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, 10:30 – 11:30 ...
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. ...
“We are extremely pleased to receive this R44 grant which will allow us to plan for a Phase 1b, doubleblind clinical study of OLX-07010 in patients with Alzheimer’s disease,” said William Erhardt, M.D., President and Head of Development at Oligomerix. “The proposed work is designed to support longerterm dosing required to assess both ...
This electrical activity, which is measurable by EEG as epileptiform discharges, may generate a vicious cycle leading to accelerated cell death and deterioration for some patients. Beacon Biosignals developed a machine learning algorithm trained to detect such epileptiform activity in patients with Alzheimer's. ...
Mission Based Media, a leader in podcasts about health, care and well-being, has launched a new podcast miniseries about Alzheimer's disease. The Alzheimer's Podcast miniseries provides insights and information for those who are diagnosed with Alzheimer's disease and the people who care about them. The miniseries was created with support from ...
” Kurve has had success in improving the lives of Alzheimer’s patients through five double-blind, placebo-controlled Phase II studies. ...
Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track Designation, as it recognizes the evidence demonstrating the potential for UB-311 to address a serious unmet medical need for patients with Alzheimer’s disease,” said Mei Mei Hu, Chief ...
ByVaxxinit
For example, Beacon is currently assessing novel EEG signatures in Alzheimer's disease patients to identify which patients may or may not benefit from a specific type of therapy. "This collaboration will enable at-home studies for diseases like Alzheimer's," Donoghue said. "It has traditionally been difficult to obtain ...
(Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the Company’s proprietary, orally dissolving thin film formulation of dexmedetomidine, for the acute ...
(NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
(NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: ...
Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary ...
The next step is to assess the blood test in a larger pool of early Alzheimer’s patients to validate it for widespread use. The Foundation for the National Institutes of Health’s Biomarkers Consortium project Plasma Abeta as a Predictor of Amyloid Positivity in Alzheimer’s Disease (up to $402,000 award) is assessing the ...
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 ...
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to ...
Although there is no conclusive data yet, Peterson points out a link between Alzheimer’s disease and lack of sleep. Sleep deprivation robs the brain of a crucial protein called amyloid beta, which results in a plaque buildup that’s similarly seen in cat scans of patients with Alzheimer’s. ...
For years, neuroscientists have been working to determine which cellular processes allow humans to learn from experience and store memories, and how these processes are compromised by conditions such as schizophrenia and Alzheimer's disease. Now, researchers from the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of Health, ...
For years, neuroscientists have been working to determine which cellular processes allow humans to learn from experience and store memories, and how these processes are compromised by conditions such as schizophrenia and Alzheimer's disease. Now, researchers from the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of Health, ...
The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center ( Chicago , Illinois ), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study. ...